Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
Conditions : NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC Stage IIIB~IV; Second-line Therapy; Metastases Interventions : Drug: Sacituzumab tirumotecan; Drug: Anlotinib Sponsors : Nanfang…
Read the full article2d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
FDA approves first-of-its-kind cholesterol pill
masslive·2h ago
STAT+: Fresh turmoil roils American Diabetes Association following controversy at conference
STAT·2h ago
Lab study finds sweetener isosteviol slows growth of key gut bacteria, especially when combined with antidepressant
the-microbiologist.com·2h agoBrain Implants Are Physically Rewiring Damaged Spines
yesilscience.com·2h ago
Predicting biotech clinical trials & a new Alzheimer’s drug controversy
STAT·3h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.